Tarsus Pharmaceuticals, Inc.
TARS
Classificação em ações
#4589
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Preço da ação
$71.12
Valor de mercado
$3.33B
Variação (1 dia)
2.33%
Variação (1 ano)
-0.10%
País
US
Negociar Tarsus Pharmaceuticals, Inc. (TARS)
Categoria
Healthcare
Lucros da Tarsus Pharmaceuticals, Inc. (TARS)
Lucros em Jun 2026 TTM: $-44.05M
De acordo com os últimos relatórios financeiros da Tarsus Pharmaceuticals, Inc., os ganhos atuais da empresa são de $-44.05M. Em 2023, a empresa teve ganhos de $-135.89M, uma diminuição em relação a aos ganhos de 2022, que foram de $-62.10M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Tarsus Pharmaceuticals, Inc. de 2018 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
